<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>VitaDAO 2024 Highlights - Hex Index</title>
  <link rel="stylesheet" href="../../styles.css">
</head>
<body class="reading-mode">
  <header class="reading-header">
    <a href="../../index.html" class="back-link">&larr; Back to Library</a>
  </header>
  <main class="reading-content">
    
    <article class="article-page">
      <header class="article-header">
        <h1>VitaDAO 2024 Highlights</h1>
        <div class="article-meta">
          <span class="author">By VitaDAO</span>
          <span class="separator">&middot;</span>
          <a href="../../publication/vitadao/index.html" class="publication">
            VitaDAO Newsletter
          </a>
          <span class="separator">&middot;</span><time>Jan 29, 2025</time>
          <span class="separator">&middot;</span>
          <span class="read-time">5 min read</span>
        </div>
      </header>

      

      <div class="article-excerpt">
        <div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!bfo0!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F83e3b31f-71aa-4272-a482-dedf0bc6dcf9_1600x900.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!bfo0!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F83e3b31f-71aa-4272-a482-dedf0bc6dcf9_1600x900.png 424w, https://substackcdn.com/image/fetch/$s_!bfo0!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F83e3b31f-71aa-4272-a482-dedf0bc6dcf9_1600x900.png 848w, https://substackcdn.com/image/fetch/$s_!bfo0!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F83e3b31f-71aa-4272-a482-dedf0bc6dcf9_1600x900.png 1272w, https://substackcdn.com/image/fetch/$s_!bfo0!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F83e3b31f-71aa-4272-a482-dedf0bc6dcf9_1600x900.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!bfo0!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F83e3b31f-71aa-4272-a482-dedf0bc6dcf9_1600x900.png" width="1456" height="819" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/83e3b31f-71aa-4272-a482-dedf0bc6dcf9_1600x900.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:819,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:null,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:null,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!bfo0!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F83e3b31f-71aa-4272-a482-dedf0bc6dcf9_1600x900.png 424w, https://substackcdn.com/image/fetch/$s_!bfo0!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F83e3b31f-71aa-4272-a482-dedf0bc6dcf9_1600x900.png 848w, https://substackcdn.com/image/fetch/$s_!bfo0!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F83e3b31f-71aa-4272-a482-dedf0bc6dcf9_1600x900.png 1272w, https://substackcdn.com/image/fetch/$s_!bfo0!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F83e3b31f-71aa-4272-a482-dedf0bc6dcf9_1600x900.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"></div></div></div></a></figure></div><h2><strong>High-Level KPIs*</strong></h2><ul><li><p>Treasury: $42M (411% YoY growth)</p></li><li><p>Token Holders: total of 8,500+ across all blockchains (250% YoY growth)</p></li><li><p>Re-org success: monthly burn rate dropped 50% from ~$100k to ~$50k</p></li></ul><p><em>*as of December 2024</em></p><h2><strong>Scientific Updates</strong></h2><p>VitaDAO's projects showed promising developments towards medicines that could slow or reverse aging by reprogramming aged cells, removing toxic aging cells, and treating other age-related conditions:</p><ul><li><p><strong>AB4AD -</strong> Successfully identified and validated 31 proteins that showed significant immune response in AD patients or controls. Some of them are preferentially targeted in Alzheimer's patients, while others may show a stronger reaction in old cognitively-intact individuals.</p></li><li><p><strong>Etheros Pharma</strong> in-vivo testing confirmed a large therapeutic window for their lead molecule, and has succeeded in creating a number of new compounds for potential new applications.</p></li><li><p>The <strong>Exercise &amp; Rapamycin clinical trial</strong> co-funded by VitaDAO under the leadership of Dr Stanfield has completed the data collection phase. Data analysis will start shortly and results should be published in a few months. <a href="https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-024-08490-2">Protocol available here</a>.</p></li><li><p><strong>Mantis Photonics</strong> tested their hyperspectral ocular imaging technology in a small clinical trial with 57 people, obtaining 93% accuracy in diagnosing Alzheimer’s. These results will be published soon.</p></li><li><p><strong>Oisin Bio</strong> published <a href="https://www.cell.com/cell/fulltext/S0092-8674(24)00783-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867424007839%3Fshowall%3Dtrue">a paper</a> on the safe and effective in vivo delivery of DNA and RNA using their proteolipid vehicles in collaboration with Entos.</p></li><li><p><strong>Remedium Bio</strong> published preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™ in a <a href="https://www.sciencedirect.com/science/article/abs/pii/S0378111924003810">paper on the Gene journal</a>.</p></li><li><p><strong>Vita-FAST</strong> went through two iterations of lead series reaching nanomolar potency at inducing autophagy.</p></li><li><p><strong>VitaRNA</strong> successfully identified from a series of candidate oligos a promising lead oligo and validated it in combination with an AAV. The project is currently raising $1M in a follow-on <a href="https://mint.molecule.to/ipnft/28/crowdsale/30703810525592972065907045517072277760884022578353069648383135471698350924972">crowdsale</a> for drug formulation and testing in animal models.</p></li></ul><p><strong>Business updates</strong></p><ul><li><p><strong>Cyclarity Therapeutics</strong> announced the <a href="https://cyclaritytx.com/cyclarity-closes-tranche-1-of-series-a-funding-round/">closing of the first tranche of its Series A</a> funding round, led by Ki Tua Fund LP and Starbloom Primrose LP. They will use the funds to commence clinical trials or the development of UDP-003, a novel therapeutic designed to reduce atherosclerotic plaque accumulation.</p></li><li><p><strong>HDAX Therapeutics</strong> <a href="https://www.businesswire.com/news/home/20240905163472/en/HDAX-Therapeutics-Announces-First-Closing-of-Oversubscribed-US-3.2-CA-4.3-Million-Seed-Financing">raised a $3.2M seed round</a> for developing HDAC6 inhibitors with blood-brain barrier penetration capabilities.</p></li><li><p>The<strong> Longevity Hackers Movie</strong> co-funded by VitaDAO has completed production and is now available in VOD on <a href="https://tv.apple.com/us/movie/longevity-hackers/umc.cmc.3ugbz6kdmqafn9g5ie0wxr627">Apple TV</a>, <a href="https://www.primevideo.com/-/it/detail/Longevity-Hackers/0PKCQMQIWF9ATMQ8VXCRTWRYU9">Prime Video</a>, <a href="https://play.google.com/store/movies/details/Longevity_Hackers?id=177EC8C9D205392CMV&amp;hl=en&amp;pli=1">Google Play</a>, Vudu, and soon on Fandango. <a href="https://www.longevityhackers.tv/">More information here</a>.</p></li><li><p><strong>Oisín Biotechnologies</strong> announces </p></li></ul>...</source>
      </div>

      <div class="read-full-article">
        <a href="https://vitadao.substack.com/p/vitadao-2024-highlights" class="read-button" target="_blank" rel="noopener">
          Read full article on VitaDAO Newsletter &rarr;
        </a>
        <p class="copyright-note">
          This excerpt is provided for preview purposes.
          Full article content is available on the original publication.
        </p>
      </div>
    </article>
  
  </main>
</body>
</html>